Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer

Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06525428 by Fudan University, with a registry enrolment figure of 96 participants, started 2024-04-01 and due to reach its primary completion in 2026-12. Interventions recorded: standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab. Conditions listed: Microsatellite Stable Metastatic Colorectal Cancer. Primary outcome: PFS. Colorectal eligibility wording from the registry: "Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum". Sites: China. No results are recorded here; the registry entry is the source.